Phase II trial of bortezomib for patients with advanced renal cell carcinoma

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
G Varuni KondaguntaRobert J Motzer

Abstract

To assess the efficacy and toxicity of bortezomib (Velcade; Milennium Pharmaceuticals Inc, Cambridge, MA; formerly PS-341) in patients with metastatic renal cell carcinoma (RCC). Thirty-seven patients with metastatic RCC were treated with bortezomib. The first 25 patients enrolled onto the trial were treated with a dose of 1.5 mg/m2. The dose was decreased to 1.3 mg/m2 for the subsequent 12 patients, because more than 50% of the patients treated at the higher dose required dose reductions. Bortezomib was given by intravenous administration on a twice-weekly schedule for 2 weeks followed by 1 week without treatment until progression or unacceptable toxicity occurred. Twenty-three patients (62%) previously had undergone nephrectomy, and 19 patients (51%) had previously been treated with cytokine therapy. Of the 37 assessable patients, the best response was a partial response in four patients (11%; 95% CI, 3% to 25%) and stable disease in 14 patients (38%; 95% CI, 23% to 55%). The four patients with partial response experienced response durations of 8, 8+, 15+, and 20+ months. Grade 2 or 3 sensory neuropathy was present in 10 patients (53%) overall. One patient in the 1.5 mg/m2 group had grade 3 sensory neuropathy; no grade 3 sens...Continue Reading

References

Jan 1, 1992·Annual Review of Biochemistry·A Hershko, A Ciechanover
Mar 1, 1989·Controlled Clinical Trials·R Simon
Aug 1, 1982·Urology·R M Snow, P F Schellhammer
Sep 19, 1996·The New England Journal of Medicine·R J MotzerD M Nanus
Dec 6, 1996·Science·R W KingM W Kirschner
Apr 18, 1998·Proceedings of the National Academy of Sciences of the United States of America·A Ciechanover, A L Schwartz
Jan 27, 2000·The Journal of Urology·R J Motzer, P Russo
Jun 27, 2003·The New England Journal of Medicine·Paul G RichardsonKenneth C Anderson
Aug 2, 2003·The New England Journal of Medicine·James C YangSteven A Rosenberg

❮ Previous
Next ❯

Citations

Jun 1, 2011·Archivum Immunologiae Et Therapiae Experimentalis·Jacek WilczynskiMalgorzata Czyz
Mar 11, 2006·Apoptosis : an International Journal on Programmed Cell Death·M LauricellaG Tesoriere
Jul 28, 2013·Investigational New Drugs·Shaji K KumarAlex A Adjei
Jun 9, 2006·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·C MontagutJ Albanell
Mar 7, 2008·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·María Cortés SempereRosario Perona
Jul 11, 2006·Nature Clinical Practice. Oncology·Tommaso CaravitaMario Boccadoro
Apr 3, 2013·Nature Reviews. Urology·Hiromi I Wettersten, Robert H Weiss
Feb 27, 2009·Journal of the National Cancer Institute·Erina VlashiFrank Pajonk
Dec 4, 2010·American Journal of Clinical Oncology·Ana M MolinaRobert J Motzer
Jan 18, 2006·Annual Review of Medicine·Paul G RichardsonKenneth C Anderson
Jan 13, 2006·Annual Review of Pharmacology and Toxicology·Peter M Voorhees, Robert Z Orlowski
Dec 14, 2011·BMC Urology·Sandra SteffensJürgen Serth
Jun 3, 2005·Cancer Cell International·Mario BoccadoroJamie Cavenagh
Mar 25, 2006·Future Oncology·Paul G Richardson, Constantine Mitsiades
Jan 8, 2008·World Journal of Gastroenterology : WJG·Michael HöpfnerHans Scherübl
Dec 17, 2008·World Journal of Gastroenterology : WJG·Michael HopfnerHans Scherubl
Jun 3, 2011·World Journal of Gastroenterology : WJG·Fawzia Bardag-Gorce
Apr 16, 2013·The International Journal of Biochemistry & Cell Biology·Linda GummlichWolfgang Dubiel
Dec 24, 2009·AJR. American Journal of Roentgenology·Chaan S NgNizar M Tannir
Aug 19, 2007·Leukemia & Lymphoma·Ashraf BadrosNancy Dawson
Nov 21, 2007·Expert Opinion on Therapeutic Targets·Antonio RussoDaniele Santini
Jan 24, 2014·Expert Opinion on Therapeutic Patents·Rainer MetcalfQ Ping Dou
Dec 26, 2006·Expert Review of Anticancer Therapy·Martin E GoreAna Montes
Jul 9, 2005·Expert Review of Anticancer Therapy·Constantine S MitsiadesKenneth C Anderson
Jun 26, 2012·Seminars in Hematology·James J Driscoll, E Steve Woodle
Jul 19, 2011·Hematology/oncology Clinics of North America·Simon ChowdhuryNizar M Tannir
Feb 6, 2010·International Journal of Radiation Oncology, Biology, Physics·Thomas J PughDavid Raben
Sep 24, 2008·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·F CaponigroA Anthoney
Mar 24, 2007·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Amalia MilanoFrancesco Caponigro
Jan 12, 2007·Experimental Neurology·Guido CavalettiRoland De Coster

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Nancy B DavisWalter M Stadler
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
Jorge CortesHagop Kantarjian
The New England Journal of Medicine
Paul RichardsonKenneth C Anderson
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Christos N PapandreouChristopher J Logothetis
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
Manisha H ShahMichael Grever
© 2021 Meta ULC. All rights reserved